Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

NCT ID: NCT05194709

Last Updated: 2022-02-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-30
• Study Completion Date: 2022-12-30

Brief Summary

This study is an interventional, single arm, open-label, investigator-initiated trial (IIT) to evaluate the safety, tolerability, initial efficacy and pharmacokinetics (PK) of anti-5T4 CAR-NK cells in patients with advanced solid tumors.

Detailed Description

The treatment cycle in this study is 21 days. The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle. Subjects will be treated continuously until the criteria for termination of treatment are met. In this study, the dose escalation design is adopted. The first administration dose in the first cycle is 3.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10^9 cells.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anti-5T4 CAR-NK Cells

Group Type: EXPERIMENTAL

Anti-CAR-NK Cells

Intervention Type: BIOLOGICAL

The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.

Interventions

Anti-CAR-NK Cells

The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Subjects volunteer to participate in this clinical study, are fully aware of the study and have signed the Informed Consent Form (ICF). Subjects are willing to follow and able to complete all trial procedures.

2. Age: adult at the age of 18-80 (both inclusive), female or male.

3. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who had failed standard therapy, or had no standard therapy, or were not eligible for standard therapy at this stage; tumor biomarkers combined with imaging can be used to diagnose some special advanced tumors.

4. Eastern Cooperative Oncology Group (ECOG) score ≤2 and expected survival time >3 months.

5. Organ function during screening should meet the following criteria:

• Absolute neutrophil count (ANC)≥0.8×109/L
• Platelet (PLT)≥50×109/L
• Hemoglobin (Hb)≥80g/L
• Total bilirubin (TBIL)≤2×ULN
• Alanine aminotransferase (ALT)≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN
• Aspartate aminotransferase (AST)≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN
• Creatinine (Cr)≤1.5× ULN
• Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5× ULN)>50ml/min/1.73m2 (Cockcroft-Gault formula)
• Activated partial thrombin time (APTT)≤1.5×ULN
• International normalized ratio (INR)≤1.5×ULN

6. Subjects of reproductive age and their partners should agree to have no family planning and to use effective contraceptive methods (hormonal or barrier methods or abstinence, etc.) for 6 months from signing the ICF until the last dose of the study drug is administered; women of reproductive age should not be pregnant or breastfeeding.

Exclusion Criteria

1. Have received systemic antitumor therapy, including chemotherapy, immunotherapy, and radical radiotherapy, within 1 week prior to their first use of the study drug.

2. Have participated in other clinical trials and received any unmarketed investigational drug or treatment within 4 weeks prior to first use of the study drug.

3. Any prior adoptive cellular immunotherapy.

4. Have undergone major organ surgery (excluding needle biopsy or surgery related to this indication) within 4 weeks prior to their first use of the study drug, or required elective surgery during the study period.

5. Patients with severe infections that cannot be controlled.

6. Patients with a known history of human immunodeficiency virus (HIV) infection, or a history of organ transplantation.

7. Have active autoimmune diseases or have had autoimmune diseases that are likely to recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.). Except in the following cases: type 1 diabetes that was well controlled with hormone replacement therapy, hypothyroidism, skin conditions that did not require systemic therapy (e.g., vitiligo), and other conditions that were well controlled and that the investigator determined were less likely to recur (e.g., childhood asthma in remission).

8. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

• There are serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia, and Ⅱ-Ⅲ degree atrioventricular block, which need clinical intervention;
• The mean QT interval corrected by Fridericia method (QTcF) is prolonged (male>450ms, female>470ms);
• Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurring within 6 months before the first administration;
• Patients with heart failure or left ventricular ejection fraction (LVEF) < 50% in the New York Heart Association (NYHA) classification ≥II;
• Hypertension beyond clinical control.

9. Adverse effects of previous antineoplastic therapy have not returned to CTCAE grade 5.0≤2 (except for toxicity that the investigator determined to be of no safety risk, such as alopecia, hypothyroidism stabilized by hormone replacement therapy).

10. Central nervous system metastases with clinical symptoms.

11. Had other malignant tumors in the past 3 years, excluding skin basal cell carcinoma, ductal carcinoma in situ and cervical carcinoma in situ with a radical surgery.

12. Have a history of alcohol or drug abuse or mental disorder.

13. The investigator considered that the subjects had a history of other serious systemic diseases or other reasons that made them unsuitable for the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Imbioray (Hangzhou) Biomedicine Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Wuxi People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peihua P Lu, MD

Role: PRINCIPAL_INVESTIGATOR

Wuxi People's Hospital

Locations

Wuxi People's Hospital

Wuxi, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Peihua Lu, MD

Role: CONTACT

lyzlyylxm@163.com

+8613583991399

Facility Contacts

Peihua Lu, MD

Role: primary

lyzlyylxm@163.com

+8613583991399

Other Identifiers

WX-IBR-8

Identifier Type: OTHER

Identifier Source: secondary_id

IBR854-T01

Identifier Type: -

Identifier Source: org_study_id